Cancer immunotherapies, including checkpoint inhibitors and adoptive cell therapy,
manipulate the immune system to recognize and attack cancer cells. These therapies have …

Abstract Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4
(CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 …

Drug-induced liver injury (DILI) is an adverse reaction to drugs or other xenobiotics that
occurs either as a predictable event when an individual is exposed to toxic doses of some …

Idiosyncratic (unpredictable) drug-induced liver injury is one of the most challenging liver
disorders faced by hepatologists, because of the myriad of drugs used in clinical practice …

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to
provide guidance on the management of immune-related adverse events resulting from …

The epidemiology and aetiology of drug‐induced liver injury (DILI) vary across different
countries and populations. Overall, DILI is rare in the general population but has become …

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies targeting immune checkpoint
molecules. ICIs are an immunotherapy for the treatment of many advanced malignancies …

Immunecheckpointinhibitors (ICIs) aremonoclonalantibodiesthat block inhibitors of T-cell
activation and function. The use of ICIs can have beneficial effects on more than 14 different …

Cancer immunotherapy, which leverages features of the immune system to target neoplastic
cells, has revolutionized the treatment of cancer. The use of these therapies has rapidly …

The application of immune checkpoint inhibitors (ICI) in advanced cancer has been a major
development in the last decade. The indications for ICIs are constantly expanding into new …